Premature physeal closure following 13‐cis‐retinoic acid and prolonged fenretinide administration in neuroblastoma |
| |
Authors: | Angela Steineck John D MacKenzie Clare J Twist |
| |
Institution: | 1. Department of Pediatrics, Stanford University School of Medicine, Stanford, California;2. Department of Radiology, University of California at San Francisco, San Francisco, California;3. Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine, Stanford, California |
| |
Abstract: | Retinoid therapy has contributed to improved outcomes in neuroblastoma. Clinical trials of fenretinide report favorable toxicity and disease stabilization in patients with high risk (HR) neuroblastoma. Skeletal effects have been described with other retinoids, but not with fenretinide to date. Two patients with HR, metastatic, refractory neuroblastoma received protracted courses of oral fenretinide for more than 5 years’ duration. Both developed premature long bone physeal closure, causing limb length discrepancies; their neuroblastoma remains in remission. The radiographic and clinical findings reported suggest these skeletal abnormalities may be a consequence of treatment with 13‐cis‐retinoic acid (13cisRA) followed by prolonged oral fenretinide exposure. |
| |
Keywords: | fenretinide late‐effects neuroblastoma pediatric oncology premature physeal closure skeletal toxicity |
|
|